Compare CRDF & ACR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | ACR |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 134.4M |
| IPO Year | 2012 | N/A |
| Metric | CRDF | ACR |
|---|---|---|
| Price | $1.80 | $18.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $9.63 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 689.6K | 14.9K |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.59 |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $1.48 | $16.51 |
| 52 Week High | $4.56 | $24.61 |
| Indicator | CRDF | ACR |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 47.50 |
| Support Level | $1.51 | $18.73 |
| Resistance Level | $2.05 | $18.98 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 16.92 | 42.46 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.